...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Additional Reports of Exempt Distribution

TOINV,

I would think that a phase 3 trial would need to be completed before an FDA nda no?? ZEN3694 does not have breakthrough status with FDA, not trying to pessimistic but if the ORR results were that good would we not here some press about the results ??  I hope you are right as that would be a slam dunk BP deal...

Share
New Message
Please login to post a reply